Zimmer Biomet (NYSE:ZBH) Lowered to “Hold” Rating by Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Several other brokerages have also recently commented on ZBH. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. Barclays cut their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 29th. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. Leerink Partners started coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 target price for the company. Finally, Truist Financial reaffirmed a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $102.70.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $87.50 on Friday. The firm has a market capitalization of $16.93 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 2.58 and a beta of 0.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The business has a fifty day moving average of $86.09 and a 200 day moving average of $89.81. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the previous year, the business earned $1.81 EPS. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts expect that Zimmer Biomet will post 8.48 earnings per share for the current year.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.28% of the stock is currently owned by company insiders.

Institutional Trading of Zimmer Biomet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DV Equities LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $25,000. Monetary Solutions Ltd purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth about $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $31,000. Flagship Harbor Advisors LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at about $32,000. Finally, Grove Bank & Trust increased its stake in shares of Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.